Last reviewed · How we verify

Schizophrenia — Treatment Landscape & Competitive Intelligence

Schizophrenia (Psychiatry) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Psychiatry 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Schizophrenia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Lybalvi SAMIDORPHAN Alkermes Inc Atypical Antipsychotic [EPC] Mu-type opioid receptor 2021-01-01
Caplyta LUMATEPERONE Intra-Cellular Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2A 2019-01-01
Aristada ARIPIPRAZOLE LAUROXIL Alkermes Inc D(2) dopamine receptor 2015-01-01
Vraylar CARIPRAZINE AbbVie Atypical Antipsychotic [EPC] D(3) dopamine receptor 2015-01-01
Rexulti BREXPIPRAZOLE Otsuka Atypical Antipsychotic [EPC] D(2) dopamine receptor 2015-01-01
Latuda LURASIDONE Sunovion Pharms Inc Atypical Antipsychotic 5-hydroxytryptamine receptor 2A 2010-01-01
Invega Sustenna PALIPERIDONE PALMITATE Johnson & Johnson Atypical Antipsychotic Potassium voltage-gated channel subfamily H member 2 2009-01-01
Fanapt ILOPERIDONE Vanda Pharms Inc Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2A 2009-01-01
Saphris ASENAPINE Hisamitsu Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2C 2009-01-01
Lonasen BLONANSERIN Dainippon Sumitomo Pharma Co., Ltd. blonanserin D(2) dopamine receptor 2008-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 13 drugs in Schizophrenia
  2. Johnson & Johnson (Janssen) · 2 drugs in Schizophrenia
  3. University of Chicago · 2 drugs in Schizophrenia
  4. Alkermes Inc · 2 drugs in Schizophrenia
  5. Bristol-Myers Squibb · 2 drugs in Schizophrenia
  6. Eli Lilly · 1 drug in Schizophrenia
  7. Hisamitsu · 1 drug in Schizophrenia
  8. Dainippon Sumitomo Pharma Co., Ltd. · 1 drug in Schizophrenia
  9. H. Lundbeck A/S · 1 drug in Schizophrenia
  10. Generic (originally Rhône-Poulenc/Sanofi) · 1 drug in Schizophrenia
  11. Generic (originally Otsuka/BMS) · 1 drug in Schizophrenia
  12. GSK · 1 drug in Schizophrenia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Schizophrenia:

Cite this brief

Drug Landscape (2026). Schizophrenia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/schizophrenia. Accessed 2026-05-13.

Related